{"id":"re-induction-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Cardiotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Re-induction therapy is a clinical strategy rather than a single drug entity, typically used in blood cancers such as acute leukemias. It involves re-treating patients with chemotherapy regimens (often similar to initial induction therapy) after relapse or to consolidate remission. The approach leverages chemosensitivity to re-establish disease control in patients whose malignant cells may have become quiescent or partially resistant.","oneSentence":"Re-induction therapy refers to a treatment protocol that re-administers chemotherapy or targeted agents to patients who have relapsed or achieved remission, aiming to restore disease control in hematologic malignancies.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:31:29.563Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute leukemia (relapsed or refractory disease)"},{"name":"Blood and hematologic malignancies requiring re-treatment"}]},"trialDetails":[{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT06669299","phase":"NA","title":"Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies","status":"RECRUITING","sponsor":"IRCCS Ospedale San Raffaele","startDate":"2025-06-12","conditions":"Ventricular Tachycardia (VT)","enrollment":51},{"nctId":"NCT04503694","phase":"PHASE2","title":"Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2021-03-25","conditions":"Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":72},{"nctId":"NCT06802523","phase":"PHASE1","title":"Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-21","conditions":"Acute Myeloid Leukemia","enrollment":53},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT07180173","phase":"","title":"Upfront Neck Dissection Before Radiotherapy in Stage N3 Nasopharyngeal Carcinoma: A Retrospective Study","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2007-04-01","conditions":"Oncology, Radiology","enrollment":7},{"nctId":"NCT07486479","phase":"PHASE3","title":"Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-10","conditions":"Acute Myeloid Leukemia (AML)","enrollment":204},{"nctId":"NCT02138734","phase":"PHASE1, PHASE2","title":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2014-07-21","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":596},{"nctId":"NCT05889494","phase":"NA","title":"Autologous Whole Blood Management for Transfusion Reduction in Adult Cardiac Surgery Patients","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2025-03-24","conditions":"Postoperative Hemorrhage, Postoperative Anemia, Postoperative Blood Loss","enrollment":64},{"nctId":"NCT06885086","phase":"","title":"ERAS (Enhanced Recovery After Surgery) and Multimodal Analgesia in Laparoscopic Cholecystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cukurova University","startDate":"2025-06-13","conditions":"Laparoscopic Cholecystectomy","enrollment":120},{"nctId":"NCT06038539","phase":"PHASE3","title":"Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Biocon Biologics UK Ltd","startDate":"2025-01-06","conditions":"HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients","enrollment":55},{"nctId":"NCT07463365","phase":"PHASE1","title":"Phase 1 Study of LUT017 Gel to Evaluate Safety and Wound Healing in Adults With Venous Leg Ulcers and Chronic Non-Healing Skin Wounds","status":"NOT_YET_RECRUITING","sponsor":"Antoni Ribas","startDate":"2026-03-02","conditions":"Venous Leg Ulcer, Chronic Non-Healing Cutaneous Wounds, VLU","enrollment":18},{"nctId":"NCT00543374","phase":"PHASE3","title":"Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2007-09-17","conditions":"Crohn's Disease","enrollment":98},{"nctId":"NCT07463378","phase":"PHASE1","title":"Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Antoni Ribas","startDate":"2026-04","conditions":"Wound Healing, Acute Skin Wounds","enrollment":9},{"nctId":"NCT06193759","phase":"PHASE1","title":"Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2024-09-20","conditions":"Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes","enrollment":12},{"nctId":"NCT04231851","phase":"PHASE2","title":"CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Irvine","startDate":"2020-02-19","conditions":"Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes","enrollment":30},{"nctId":"NCT02835222","phase":"PHASE2","title":"Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-02-02","conditions":"Untreated Adult Acute Myeloid Leukemia","enrollment":57},{"nctId":"NCT07451678","phase":"PHASE4","title":"Treatment of Blepharitis Induced by Demodex Folliculorum Through Eyelid Cleansing With Wipes Containing Topical Chlorhexidine","status":"COMPLETED","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2024-07-01","conditions":"Blepharitis","enrollment":106},{"nctId":"NCT04656951","phase":"PHASE2","title":"Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cologne","startDate":"2021-06-01","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT06773936","phase":"PHASE2","title":"Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","status":"ENROLLING_BY_INVITATION","sponsor":"SWOG Cancer Research Network","startDate":"2026-05-15","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia","enrollment":55},{"nctId":"NCT07409844","phase":"PHASE2","title":"Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Ismail Gögenur","startDate":"2026-03-01","conditions":"DMMR Colorectal Cancer, Colon Cancer Stage I, Colon Cancer Stage II/III","enrollment":152},{"nctId":"NCT02224781","phase":"PHASE3","title":"Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-08","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma","enrollment":267},{"nctId":"NCT06122480","phase":"NA","title":"Surgical Resection of Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-05-21","conditions":"Pancreatic Ductal Adenocarcinoma, Oligometastatic Disease","enrollment":5},{"nctId":"NCT07408648","phase":"PHASE2","title":"A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-04-15","conditions":"Chemotherapy Induced Thrombocytopenia","enrollment":244},{"nctId":"NCT07329699","phase":"NA","title":"Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)","status":"NOT_YET_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2026-03-01","conditions":"Coronary Artery Disease, Chronic Coronary Syndrome, Acute Coronary Syndrome","enrollment":2100},{"nctId":"NCT02875314","phase":"PHASE4","title":"HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parth Patel","startDate":"2015-09","conditions":"Medulloblastoma, Central Nervous System Embryonal Tumors","enrollment":250},{"nctId":"NCT07402538","phase":"PHASE3","title":"Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Oral Cancer, Oropharyngeal Cancer","enrollment":184},{"nctId":"NCT07082179","phase":"PHASE2","title":"A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-09-04","conditions":"NSCLC","enrollment":33},{"nctId":"NCT07399158","phase":"","title":"CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Response to Induction Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-02-01","conditions":"Nasopharyngeal Carcinoma","enrollment":223},{"nctId":"NCT05333874","phase":"EARLY_PHASE1","title":"CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2022-04-06","conditions":"Breast Cancer, Early-Onset","enrollment":34},{"nctId":"NCT07371234","phase":"PHASE2","title":"Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Xiwei XU","startDate":"2025-12-15","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":22},{"nctId":"NCT04681105","phase":"PHASE1","title":"Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2020-11-18","conditions":"Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":13},{"nctId":"NCT06490172","phase":"NA","title":"Shock Wave Therapy as a Treatment Intervention for Frozen Shoulder","status":"NOT_YET_RECRUITING","sponsor":"University of Stirling","startDate":"2026-05","conditions":"Shoulder Pain, Adhesive Capsulitis of Shoulder","enrollment":18},{"nctId":"NCT07358676","phase":"PHASE2","title":"A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-01","conditions":"Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage","enrollment":25},{"nctId":"NCT07359339","phase":"NA","title":"Microneedling With Platelet Rich Plasma Versus Microneedling Alone For Gingival Depigmentation","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-10-01","conditions":"Gingival Pigmentation","enrollment":32},{"nctId":"NCT05317000","phase":"PHASE2","title":"5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC","status":"RECRUITING","sponsor":"Barbara Burtness","startDate":"2023-03-23","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":50},{"nctId":"NCT05270096","phase":"","title":"International Leukemia Target Board","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2022-12-31","conditions":"Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy","enrollment":600},{"nctId":"NCT05013190","phase":"","title":"A Study of NINLARO® in Chinese Adults With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2021-10-29","conditions":"Multiple Myeloma","enrollment":72},{"nctId":"NCT07308054","phase":"NA","title":"The Effects of Fresnel Prism Glasses on Visual Perception, Balance, Gait and Functional Independence in Post-Stroke Patients","status":"NOT_YET_RECRUITING","sponsor":"Lahore University of Biological and Applied Sciences","startDate":"2025-12-13","conditions":"Stroke","enrollment":50},{"nctId":"NCT04269213","phase":"PHASE2","title":"CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2021-07-29","conditions":"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid Leukemia","enrollment":21},{"nctId":"NCT05761171","phase":"PHASE2","title":"A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2024-01-08","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage","enrollment":78},{"nctId":"NCT07277764","phase":"PHASE2","title":"Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)","status":"RECRUITING","sponsor":"Jiangxi Provincial Cancer Hospital","startDate":"2025-10-10","conditions":"Nasopharyngeal Carcinoma (NPC), Recurrent Nasopharyngeal Neoplasms","enrollment":23},{"nctId":"NCT01723774","phase":"PHASE2","title":"PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2013-04-10","conditions":"Breast Neoplasms","enrollment":84},{"nctId":"NCT05024552","phase":"PHASE1","title":"Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-02-25","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation","enrollment":22},{"nctId":"NCT04373031","phase":"PHASE2","title":"Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2020-12-30","conditions":"Breast Cancer, Breast Neoplasms","enrollment":12},{"nctId":"NCT03945162","phase":"PHASE2","title":"Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients","status":"RECRUITING","sponsor":"Theralase® Technologies Inc.","startDate":"2019-08-30","conditions":"Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Unresponsive/Intolerant to BCG","enrollment":90},{"nctId":"NCT05845112","phase":"","title":"Start Taking Action For TB Diagnosis","status":"COMPLETED","sponsor":"Liverpool School of Tropical Medicine","startDate":"2025-02-28","conditions":"Diagnosis, Tuberculosis","enrollment":14747},{"nctId":"NCT05535738","phase":"PHASE2, PHASE3","title":"Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation","status":"RECRUITING","sponsor":"Wei-Che Ko","startDate":"2022-11-15","conditions":"Skin Inflammation, Allergic Contact Dermatitis","enrollment":45},{"nctId":"NCT04801797","phase":"PHASE2","title":"Venetoclax + Azacitidine vs. Induction Chemotherapy in AML","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2021-05-20","conditions":"Acute Myeloid Leukemia","enrollment":172},{"nctId":"NCT03900949","phase":"PHASE1","title":"Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Uma Borate","startDate":"2019-03-13","conditions":"Acute Myeloid Leukemia","enrollment":21},{"nctId":"NCT02756962","phase":"PHASE2","title":"Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2016-07-06","conditions":"Acute Myeloid Leukemia","enrollment":107},{"nctId":"NCT05761756","phase":"NA","title":"Oxygen Toxicity: Mechanisms in Humans","status":"RECRUITING","sponsor":"Duke University","startDate":"2023-11-28","conditions":"Oxygen Toxicity, Hypercapnia, Seizures","enrollment":62},{"nctId":"NCT06829823","phase":"PHASE2","title":"Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11","conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":20},{"nctId":"NCT03022825","phase":"PHASE2, PHASE3","title":"QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2017-06-02","conditions":"Bladder Cancer","enrollment":190},{"nctId":"NCT06280716","phase":"PHASE3","title":"A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-04-24","conditions":"Atopic Dermatitis","enrollment":301},{"nctId":"NCT06257875","phase":"PHASE2","title":"A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-03-23","conditions":"Ulcerative Colitis","enrollment":156},{"nctId":"NCT04012073","phase":"PHASE3","title":"Individualized Positive End-expiratory Pressure Guided by End-expiratory Lung Volume in the Acute Respiratory Distress Syndrome","status":"TERMINATED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2022-11-01","conditions":"Respiratory Distress Syndrome, Adult","enrollment":18},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT02917720","phase":"PHASE2","title":"2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"European LeukemiaNet","startDate":"2016-09","conditions":"Chronic Myeloid Leukemia","enrollment":75},{"nctId":"NCT06621212","phase":"PHASE2","title":"Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-07-05","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":72},{"nctId":"NCT01920737","phase":"PHASE2","title":"A Novel \"Pediatric-Inspired\" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-08-07","conditions":"Leukemia","enrollment":39},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT07162090","phase":"PHASE4","title":"Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-10","conditions":"Sarcopenia, Anemia Associated With Chronic Kidney Disease (CKD), Dialysis Patients","enrollment":60},{"nctId":"NCT05576480","phase":"PHASE2","title":"SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2023-02-06","conditions":"Rectal Cancer, Locally Advanced","enrollment":55},{"nctId":"NCT07132463","phase":"PHASE3","title":"Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-08","conditions":"Rectal Cancer","enrollment":154},{"nctId":"NCT06267391","phase":"NA","title":"Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes","status":"RECRUITING","sponsor":"Endogenex, Inc.","startDate":"2024-05-01","conditions":"Type 2 Diabetes Mellitus, Type2diabetes, Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT03793478","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2018-08-15","conditions":"Acute Myeloid Leukemia","enrollment":65},{"nctId":"NCT07078591","phase":"PHASE2","title":"Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2025-06-20","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT03547999","phase":"PHASE2","title":"A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC","status":"TERMINATED","sponsor":"Patrick Boland","startDate":"2018-06-26","conditions":"Metastatic Colorectal Cancer","enrollment":17},{"nctId":"NCT04062708","phase":"PHASE2","title":"CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2021-03-10","conditions":"Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer","enrollment":38},{"nctId":"NCT04594772","phase":"PHASE2","title":"Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2021-03-17","conditions":"Pancreas Cancer","enrollment":32},{"nctId":"NCT07030140","phase":"PHASE2","title":"Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-07-01","conditions":"Cholangiocarcinoma, Hilar Cholangiocarcinoma, Bile Duct Cancer","enrollment":38},{"nctId":"NCT02401503","phase":"PHASE2","title":"Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2015-05-06","conditions":"Chronic Lymphocytic Leucemia","enrollment":66},{"nctId":"NCT06257394","phase":"PHASE2","title":"Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea","status":"RECRUITING","sponsor":"Hyoung Jin Kang","startDate":"2024-10-20","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":74},{"nctId":"NCT01860937","phase":"PHASE1","title":"T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-05","conditions":"Relapsed B-Cell Acute Lymphoblastic Leukemia","enrollment":23},{"nctId":"NCT05470777","phase":"PHASE2","title":"CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-01-19","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":37},{"nctId":"NCT05851924","phase":"PHASE2","title":"A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-05-12","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT06998719","phase":"PHASE2","title":"Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Bi Nan","startDate":"2025-07","conditions":"Non-small Cell Lung Cancer Stage III, Borderline Resectable Carcinoma","enrollment":80},{"nctId":"NCT06761287","phase":"NA","title":"Optimizing Patient Selection for Surgery Using Pathologic Analysis Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Saint Pierre","startDate":"2025-03-28","conditions":"Locally Advanced Rectal Cancer (LARC)","enrollment":20},{"nctId":"NCT01044069","phase":"PHASE1","title":"Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-01-05","conditions":"Leukemia, Acute Lymphoblastic Leukemia","enrollment":93},{"nctId":"NCT03534141","phase":"NA","title":"Mild Hypothermia and Acute Kidney Injury in Liver Transplantation","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2018-07-07","conditions":"Cirrhosis, End Stage Liver Disease, Acute Kidney Injury","enrollment":175},{"nctId":"NCT04219540","phase":"PHASE4","title":"Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2021-01-07","conditions":"Opioid-use Disorder","enrollment":675},{"nctId":"NCT06969781","phase":"NA","title":"MWA With or Without Furmonertinib for Early-Stage Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-05","conditions":"Lung Cancer (NSCLC)","enrollment":120},{"nctId":"NCT03560908","phase":"PHASE1","title":"Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation","status":"WITHDRAWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2018-07-01","conditions":"Relapsed AML, T(8;21), C-KIT Mutation","enrollment":""},{"nctId":"NCT03782376","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"Janssen-Cilag Ltd.","startDate":"2018-12-20","conditions":"Crohn Disease","enrollment":215},{"nctId":"NCT01396655","phase":"PHASE2","title":"PET in Breast Cancer Receiving Neoadjuvant Chemotherapy","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2006-07","conditions":"Breast Cancer","enrollment":78},{"nctId":"NCT06909721","phase":"NA","title":"Misoprostol Versus Dinoprostone in Induction of Labor","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2023-06-10","conditions":"Induction of Labor","enrollment":200},{"nctId":"NCT06887855","phase":"NA","title":"Enhancing Post-Stroke Dysphagia Rehabilitation","status":"RECRUITING","sponsor":"Hamad Medical Corporation","startDate":"2024-11-01","conditions":"Dysphagia After Stroke","enrollment":10},{"nctId":"NCT06735287","phase":"NA","title":"A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-01","conditions":"Bladder Cancer, NMIBC","enrollment":60},{"nctId":"NCT04632433","phase":"PHASE2","title":"Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Melanoma Onlus","startDate":"2021-02-10","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":25},{"nctId":"NCT06663098","phase":"PHASE2","title":"Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).","status":"RECRUITING","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2025-01-24","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":142},{"nctId":"NCT05536726","phase":"PHASE3","title":"A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2023-01-07","conditions":"Psoriasis","enrollment":458},{"nctId":"NCT06668441","phase":"PHASE1","title":"Minimally Invasive Surgery and RhTNK-tPA for Intracerebral Hemorrhage Evacuation","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2024-11-04","conditions":"Intracranial Hemorrhages, Cerebrovascular Disorders, Cerebral Hemorrhage","enrollment":12},{"nctId":"NCT04049539","phase":"PHASE1, PHASE2","title":"Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2021-01-29","conditions":"Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Persistent Disease, Refractory Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT05430035","phase":"EARLY_PHASE1","title":"Safety and Feasibility of HIPEC for High-Risk Gallbladder Adenocarcinoma","status":"RECRUITING","sponsor":"West Virginia University","startDate":"2022-06-23","conditions":"Gallbladder Adenocarcinoma","enrollment":10},{"nctId":"NCT04977180","phase":"PHASE2","title":"Cardioprotection in AML","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2022-03-04","conditions":"AML, Acute Myeloid Leukemia","enrollment":70},{"nctId":"NCT03992664","phase":"NA","title":"Education Intervention in Patients with Rash Due to Epidermal Growth Factor Receptor (EGFR) Treatment.","status":"COMPLETED","sponsor":"Cyprus University of Technology","startDate":"2019-01-01","conditions":"Consent Form, Lung Cancer, Colon Cancer","enrollment":40},{"nctId":"NCT06806553","phase":"NA","title":"Constraint-Induced Movement Therapy (CIMT) with Motor Relearning Program (MRP) and Bobath Approach to Augment Functional Motor Recovery of Chronic Hemiparetic Arm","status":"COMPLETED","sponsor":"University of Lahore","startDate":"2024-01-26","conditions":"Stroke, Hemiparesis, Hemiparesis After Stroke","enrollment":64},{"nctId":"NCT04685577","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Nefopam Cream in Burn Patients","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2022-07-10","conditions":"Burn; Multiple Body Regions, Max. Second Degree, Third-Degree Burn, Burn Degree Second","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":108,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Re-induction Therapy","genericName":"Re-induction Therapy","companyName":"Institute of Hematology & Blood Diseases Hospital, China","companyId":"institute-of-hematology-blood-diseases-hospital-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Re-induction therapy refers to a treatment protocol that re-administers chemotherapy or targeted agents to patients who have relapsed or achieved remission, aiming to restore disease control in hematologic malignancies. Used for Acute leukemia (relapsed or refractory disease), Blood and hematologic malignancies requiring re-treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}